Evaluation
*
HighAbove AverageAverageBelow AverageLow
Melanie E. Royce, MD, PhD
Karen Herold, DNP, FNPOBC, WHCNP-BC
*
Strongly AgreeAgreeNeutralDisagreeStrongly Disagree
Describe scientific updates and key practice changes in the management of advanced HER2-positive breast cancer
Review HER2 testing guidelines for patients with breast cancer
Discuss best sequencing of FDA approved targeted agents, mechanism of action and toxicities
Explain the role of neoadjuvant chemotherapy in HER2-positive breast cancer, including use of HER2-targeted agents
Describe collaboration between various members of the healthcare team (including but not limited to physician, advanced practitioner, and pharmacist) in management strategies for patients with advanced HER2 positive breast cancer
*
Strongly AgreeAgreeNeutralDisagreeStrongly Disagree
This activity met my educational needs, expectations, and objectives
This activity was relevant to my practice
I feel confident treating patients in my practice based on this activity
This activity rates highly in comparison with other CE/CME activities in which I have participated in the last 12 months
The presentation was scientifically sound and free of commercial bias or influence
*
*
*
*
*